Overview

Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Phase IV, randomized, double-masked, parallel-group clinical trial comparing the ocular tolerability and steroid-induced intraocular pressure (IOP) effects of Zylet wth that of TobraDex in healthy volunteers, when either product was administered QID (at approximately 4-hour intervals) for 28 days.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Loteprednol Etabonate
Tobramycin